Morningstar1mon
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Ferumoxtran is an MRI Contrast Agent that may be used to detect lymph node metastases as small as 2 mm in prostate cancer patients. Sanochemia has secured exclusive global commercialization rights ...
pharmaphorum1mon
Bayer reveals phase 3 data for improved MRI contrast agent
Bayer is on the brink of filing a new MRI contrast agent for approval that can reduce levels of gadolinium, a rare earth metal that can have health and environmental consequences. The company has ...
Nature1y
In vivo visualization of gene expression using magnetic resonance imaging
using an MRI contrast agent that can indicate reporter gene expression in living animals. We have prepared MRI contrast agents in which the access of water to the first coordination sphere of a ...
pharmaphorum5y
FDA clears Bayer’s Gadavist as first contrast agent for cardiac MRI
The magnetic resonance imaging (MRI) contrast agent – based on gadobutrol – has been cleared by the FDA for cardiac MRIs on the back of two phase 3 trials which showed it was safe and ...